Epitopea was created by CTI and based in Montreal, Canada and Cambridge, UK. The company was founded based a novel tumor specific antigen (TSA) discovery platform from IRICoR at University of Montreal. The company is leveraging these novel TSAs and developing them into cancer vaccine against solid tumors, and exploring their use in other modalities such as TCR therapies.
Cancer vaccine platform
CTI LSF III
Co-Lead
Director & Observer
November 25, 2011
Active
Seed
Epitopea had a novel approach to identify tumor specific antigens that are highly immunogenic and shared across patients to enable true off-the-shelf cancer vaccines
